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Phenytoin (PHT) is one of the most often used critical dose drugs, where insuﬃcient or excessive dosing can have severe con-
sequences such as seizures or toxicity. +us, the monitoring and precise measuring of PHTconcentrations in patients is crucial. +is
study develops and validates an LC-MS/MS method for the measurement of phenytoin concentrations in diﬀerent body com-
partments (i.e., human brain dialysate, blood, and saliva) and compares it with a formerly developed GC-MS method that measures
PHT in the same biological matrices. +e two methods are evaluated and compared based on their analytical performance, ap-
propriateness to analyze human biological samples, including corresponding extraction and cleanup procedures, and their validation
according to ISO 17025/FDA Guidance for Industry. +e LC-MS/MS method showed a higher performance compared with the
GC-MS method. +e LC-MS/MS was more sensitive, needed a smaller sample volume (25 µL) and less chemicals, was less time
consuming (cleaning up, sample preparation, and analysis), and resulted in a better LOD (<1 ng/mL)/LOQ (10 ng/mL). +e
calibration curve of the LC-MS/MS method (10–2000 ng/mL) showed linearity over a larger range with correlation coeﬃcients
r2> 0.995 for all tested matrices (blood, saliva, and dialysate). For larger sample numbers as in pharmacokinetic/pharmacodynamic
studies and for bedside as well as routine analyses, the LC-MS/MS method oﬀers signiﬁcant advantages over the GC-MS method.
1. Introduction
Sensitive and speciﬁc quantiﬁcation methods are of critical
importance whenmonitoring individualized drug therapy in
patients or investigating drug concentration in forensic
toxicology [1]. Critical dose drugs but also newly developed
and designed complex drugs require analytical methods to
check for eﬀective drug delivery to target tissues and to
minimize toxicity in sensitive organs or cells. When such
drugs have to be used in patients with varying pharmaco-
kinetics (PK) (e.g., ICU patients), an appropriate therapeutic
drug monitoring (TDM), which allows, for example, to
correlate the drug concentration in easy accessible plasma
samples with those in the tissue of action, becomes even
more relevant for a safe and eﬃcient drug treatment [2].
Phenytoin (PHT) belongs to the most widely prescribed
drugs to prevent and control most types of seizure disorders
and to treat epilepsy [3]. It is one of the most often used
critical dose drugs where insuﬃcient or excessive dosing can
have severe consequences such as seizures or toxicity. +us,
the monitoring and precise measuring of PHT concentra-
tions in patients is crucial [4, 5]. As an example, in forensic
toxicology, epilepsy patients under PHT treatment who have
been involved in an accident have to be analyzed in order to
verify whether the PHT concentration was adequate or
possibly the reason for the accident [6]. However, there are
several characteristics of PHT including a relatively low
therapeutic index, diﬃcult pharmacokinetics (PK) and phar-
macodynamics (PD), saturable oxidative biotransformation,
and the nonlinear clearance, which complicate a therapeutic
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drug monitoring (TDM) aimed at preventing intoxication of
patients or treatment failures [7].
+us, researchers and practitioners are interested in
speciﬁc, sensitive, robust, and cost-eﬀective methods to
identify PHT concentrations in patients. +ereby, several
compartments to measure the PHT concentration could be
addressed such as blood, saliva, and CNS ﬂuid (micro-
dialysate). +e correlation of PHT in diﬀerent body com-
partments is not yet completely understood and has only
recently been addressed by researchers who have compared
the measurement of PHT in these diﬀerent compartments
with a GC-MS method [8]. While the GC-MS has long been
the standard method in forensic testing, LC-MS/MS methods
have become more common, as they generally oﬀer some
advantages over GC-MS [9]. Recently, researchers have de-
veloped an LC-MS/MS method to measure PHT in one
speciﬁc body compartment (i.e., blood plasma or serum) [10].
Missing, however, is a thorough comparison of the perfor-
mance of these two analytical methods in the detection and
analysis of PHT in diﬀerent body compartments (i.e., blood,
saliva, and samples from brain tissue microdialysis).
+e aim of the present study was to develop and validate
an LC-MS/MS method for the measurement of PHT con-
centrations in diﬀerent body compartments such as blood
and saliva, as well as samples from brain tissue microdialysis
often used in neurology and neurosurgery, where antiepi-
leptic therapy is often mandatory [11, 12], and to compare its
eﬃciency with a formerly developed GC-MS method [8].
+e fact that this established GC-MSmethod measured PHT
in the same biological matrices (i.e., blood, saliva, and hu-
man brain dialysate) enables a reliable comparison with
regard to the performance of GC-MS versus LC-MS/MS in
measuring PHT in diﬀerent body compartments. +e two
methods are evaluated and compared based on their ana-
lytical performance, appropriateness to analyze human bi-
ological samples, including corresponding extraction and
cleanup procedures, and their validation according to ISO
17025/FDA Guidance for Industry [13]. Finally, the suit-
ability of the two analytical methods for PK/PD studies,
bedside measurement, and forensic use is discussed. In
addition, the LC-MS/MS method developed in the current
study is compared with an established LC-MS/MS method
which measured PHT in blood plasma samples [10].
2. Materials and Method
2.1. Chemicals and Samples Used for the Development of the
LC-MS/MS Method and Its Validation. PHT reference
substance was purchased from Desitin Pharma GmbH
(Liestal, Switzerland) and from the European Pharma-
copoeia (PHT Ph. Eur. Standard, EDQM, Strasbourg,
France). +e IS for LC-MS/MS was PHT-D10 (PHT D-10,
C15H2D10N2O2, MW� 262.33) in methanol (MeOH)
(100 μg/mL) from Cerilliant (Round Rock, TX).
Calcium chloride, perchloric acid, citric acid mono-
hydrate, potassium chloride, magnesium chloride hexahy-
drate, sodium chloride, sodium hydroxide, and the solvents
(methanol, acetic acid 100%, and acetone) were of analytical
grade and purchased from Merck (Darmstadt, Germany).
Artiﬁcial cerebrospinal ﬂuid (aCSF; dialysate solution) was
prepared according to M Dialysis AB (Stockholm, Sweden)
[14]. Blood CPDA-1 (anticoagulant citrate phosphate dex-
trose adenine solution; to simplify only named blood in the
following) was obtained from the Blood Donor Center
(Bern, Switzerland). Saliva was obtained from one of the
investigators. 20–60 μL PHT-containing samples from pa-
tients collected from a 2 µL/min ﬂow rate brainmicrodialysis
and 2mL of CPDA containing PHT patient blood samples
were provided by the Department of Neurosurgery (Kant-
onsspital Aarau AG, Switzerland and Centre Hospitalier
Universitaire Vaudois, Switzerland). All biological samples
(blood and dialysates) were frozen and stored at −24°C.
Before sample analysis, the samples were thawed at room
temperature for 30 minutes and homogenized by shaking
with a vortex for one minute.
2.2. Internal Standards, Calibrator Standard System Suit-
ability Testing, and Sample Preparation. +e internal stan-
dard (IS) stock solution was prepared by adding 100 µL of
the PHT-D10 (100 µg/mL) to 9900 µL of MeOH. 5mL of this
solution was added to 95mL of 1M perchloric acid aqueous
solution to get the ﬁnal concentration of 50.0 ng/mL, which
is used as IS working solution. +e PHT reference stock
solution (1.00mg/mL) was used to obtain eight calibration
(Cal) solutions with concentrations of 2000, 1000, 500, 250,
100, 50, 20, and 10 ng/mL PHT. 20 µL of these Cal solutions
were added to 980 µL of the biomatrices to get the Cal
working solutions. For quality control (QC), solutions with
1600, 400, 30, and 10 ng/mL PHTwere prepared out of PHT
reference stock solution (1.00mg/mL).
+e IS working solution of 75 µL was added either to an
aliquot of 25 µL Cal working solution, QC solutions, or 25 µL
sample from patients containing PHT. +e sample prepa-
ration for the LC-MS/MS consisted of pipetting 75 µL of IS
working solution to 25 µL sample into a deep well plate
(0.6mL, Chemie Brunschwig AG, Basel, Switzerland) cov-
ered by a sealing mat (Silicone, Chemie Brunschwig AG,
Basel, Switzerland). +e well plates were rigorously shaken
for 5 minutes and then centrifuged (4.500U/min; Mikro
22R, Hettich Instruments, Andreas Hettich AG, Ba¨ch,
Switzerland) for 30 minutes at about 8°C (Figure 1). +e
processed samples were ready for the LC-MS/MS analysis.
2.3. LC-MS/MS Settings. +e prepared samples were placed
into the autosampler (Dionex WPS-3000TSL Olten, Swit-
zerland) which was set at 8°C. With a100 µL syringe from the
autosampler, 10 µL of the prepared samples was injected into
a 130 µL loop. +e solvent rack (Dionex SRD-3600, Olten,
Switzerland) carried the mobile phase A (H2O+HCOOH
(100+ 0.1, v + v)) and phase B (MeCN+HCOOH (100+ 0.1, v
+ v)). +ese mobile phases were delivered by three pumps
(binary pump 1 (ﬂow 0.350mL/min) and isocratic pump 2
(ﬂow 0.200 to 1.000mL/min) (Dionex pump HPG-3200A,
Olten, Switzerland), and binary pump 3 (Dionex pump ISO-
3100A, Olten, Switzerland)) connected to a triple stage
quadrupole mass spectrometer with linear ion-trap capability
(3200 QTrap, Analyst Software Version 1.5.1, Applied
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Biosystems/MDS Sciex, Toronto, Canada) (Table 1). For the
mass spectrometric detection, SRM scan mode (selective
reaction monitoring) was used. SRM transitions and mass
spectrometric conditions were as follows: transition:
253.1→ 182.2 (PHT) and 253.1→ 192.2 (PHT-D10); orice (V):
36; collision energy (eV): 41 (PHT) and 51 (PHT-D10); and
dwell time (msec): 100. Electrospray ionization was per-
formed in positive ion mode for the analyte and the IS. e
following instrument parameters for ionization were used: ion
source voltage: 5000 volt, curtain gas: 25, gas 1: 40 and gas
2: 60; and the CAD gas was set to 5 (arbitrary units for the
gas settings). As trapping column, a Phenomenex Gemini
Polar column (2.0×10mm, 5µm; Brechbu¨hler AG, Schlieren,
Switzerland) temperated to room temperature was used. e
main column Phenomenex Synergy Polar RP column
(2.0× 50mm; Brechbu¨hler AG, Schlieren, Switzerland) was
placed into the column oven (Cluzeau Info Labo CrocoCil)
set on 50°C with a column thermostat (Dionex TCC-3100,
Olten, Switzerland) including switching valve (Figure 2).
is systemwas operated by Analyst Software (Version 1.5.1,
AB Sciex, Toronto, Canada).
2.4. Validation of the LC-MS/MS Method according to ISO
17025/FDA Guidance for Industry. e validation was car-
ried out according to ISO 17025/FDAGuidance for Industry
including selectivity, sensitivity, accuracy, recovery of PHT,
reproducibility and suitability of the calibration curves,
stability of PHT, and matrix eects. e selectivity and
sensitivity (absence of PHT) were veried by analyzing blank
samples without PHT (extraction andmatrix eects). For the
accuracy, QCs and Cal samples were analyzed. e recovery
of PHT was analyzed by measuring QCs at dierent levels.
e reproducibility and suitability of the calibration curves
was measured by a complete series of Cal 1 to Cal 8
(LC-MS/MS) analyses. e limit of detection (LOD) and
the limit of quantication (LOQ) were analyzed using Cal 1
(LC-MS/MS 10 ng/mL PHT). e LOD was checked as a
signal-to-noise (S/N) ratio of more than 4 :1. e LOQ was
considered as 5 times the response to a blank sample. e
stability tests consisted of the freeze-thaw stability of PHT,
which was determined after 3 freeze-thaw cycles. e short-
term stability was analyzed by keeping the samples thawed at
ambient temperature for at least 6 hours, frozen for at least
12 hours at −25°C± 5°C, and again thawed, worked-up, and
analyzed. Postpreparative stability was evaluated to determine
whether an analytical run can be reinjected in the case of
instrument failure and, furthermore, whether the preparation
of a large number of samples could be done at once.
erefore, one of the validation runs was analyzed a second
time after 7 days. e described criteria for Cal curves, QC,
accuracy, and precision had to be met.
25 μL sample and
75 μL of HCIO4 with
D10-PHT was
pipetted into the
deep well plate
(DWP)
e DWP was
certrifuged for 30 min
(4500 U/min) at 8ºC
e centrifuged DWP
was placed into the LC-
MS autosampler and 10 μL
of the worked-up
sample was injected
Figure 1: Sample preparation for the LC-MS/MS analyses for blood, saliva, and aCSF samples.
Table 1: Settings of the HPLC program.
Time
(minutes)
Pump 1 (main column (MC)) Pumps 2 and 3 (trapping column (TC))
%B Flow(µL/min) Comments %B
Flow
(µL/min)
Flow pump 5
(H2O+ 0.1% HCOOH) (µL/min)
Switching valve
0 35
500
Start MS and pumps 50 300 800 TC → waste, MC → MS (loading)
0.5 35 Start gradient 50 300 800 TC → MC → MS (eluting)
0.6 ↓
50 20 201 97.5
2 97.5 TC → waste, MC → MS
2.5 35 50 300 800 Reequilibration
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Matrix eects were analyzed by comparing the cali-
bration curves generated with the three matrices aCSF,
blood, and saliva. PHT microdialysis and blood samples
from patients were analyzed to demonstrate the suitability of
the method for biological samples from patients.
2.5. Comparison of the LC-MS/MS and the GC-MS
Method. e LC-MS/MS method was evaluated and com-
pared with the GC-MS method published by Ho¨sli et al. [8]
with regard to its analytical performance, appropriateness to
analyze human biological samples, including corresponding
extraction and cleanup procedures, and its validation
according to ISO 17025/FDA Guidance for Industry.
e statistical data were calculated with Microsoft Excel
and IBM SPSS Statistics 22. To compare the dierent ma-
trices, a one-way ANOVA was calculated. e corre-
sponding values were checked for signicance by t-tests.
3. Results
3.1.Validation of the LC-MS/MSMethod. e retention time
(RT) for PHT and for PHT-D10 (IS) was about 2.8min
(Figure 3). e selectivity and sensitivity were checked; all
blank samples were negative. e recovery of PHT after
precipitation with HClO4 was 89.5% for QC1 (10 ng/mL)
and 97.1% for QC3 (1600 ng/mL) compared to the amount
found in unprepared samples (100%). e LOD calculated
as S/N ratio of 4 :1 for this method in aCSF, saliva, and blood
was set at <1 ng/mL. e LOQ calculated as 5 times the
response/blank was 10 ng/mL PHT. For the accuracy, the
Cal 1 to Cal 8 were assessed. e calibrator values showed
min–max deviations of 1–8% for Cal 2 (20 ng/mL) to Cal 8
(2000 ng/mL) with 3% for Cal 1 (10 ng/mL). e calibration
curves for all three matrices were linear. e regression co-
e©cients (r2) of the three dierent matrices were r2blood 0.996
(n  3), r2dialysate  0.997 (n  6), and r2saliva 0.995 (n  3).
Reinjection after 7 days showed no dierence in accuracy.
e sample volume needed was 25 µL. e sample prep-
aration time was about 2min per sample (6 hours for
182 samples). e run time for one LC-MS/MS analyses
was 7min.
3.2. Comparison of the LC-MS/MS with the GC-MS
Method. After validation of the LC-MS/MS method, it
was compared with the referred GC-MS method [8]. Table 2
shows the comparative results of the two methods for their
analytical performance, appropriateness to analyze human
biological samples, including corresponding extraction and
cleanup procedures, and its validation according to ISO
17025/FDA Guidance for Industry (Table 2).
e selectivity and the sensitivity were met by both
methods, and the recovery showed no dierences (Table 2).
But the accuracy diered between the twomethods.e GC-
MS method showed a higher variation at Cal 1 (20%) than
the LC-MS/MS method (Cal 1 3%). As expected, the
biggest dierence in terms of analytical performance
between the two methods was observed by the LOQ (GC-
MS 50 ng/mL; LC-MS/MS 10 ng/mL) and LOD (GC-
MS 15 ng/mL; LC-MS/MS<1 ng/mL) (Table 2).
Both methods showed linear regression coe©cients (r2)
higher than 0.995 in all three dierent matrices for the PHT
calibration curve. e calibration range of the LC-MS/MS
Isocratic pump
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column
ESI-MS/MS
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n
T-union
Autosampler
Waste
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m
n
Binary pump 1 Binary pump 2
Analytical
column
Analytical column
ESI-MS/MS
T-union
Autosampler
Waste
Isocratic pump
Eluting
(b)
Figure 2: LC-MS/MS settings.
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(from 10 ng/mL to 2000 ng/mL) is twice as large as of the
GC-MS (50 ng/mL to 1200 ng/mL). +e stability of the
samples after extraction and cleaning up was demonstrated
for both methods. +e sample preparation procedure is
demonstrated in Figure 1 for LC-MS/MS and Figure 4 for
GC-MS.
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Figure 3: Chromatogram of phenytoin (illustrated for LOQ (10 ng/mL) and QC3 (400 ng/mL)) with PHT-D10 as IS (50 ng/mL).
Table 2: Comparison of the GC-MS [8] versus LC-MS/MS method.
Criterion GC-MS LC-MS/MS
Retention time PHT 15.12min, IS MPPH 16.15min PHT and PHT-D10 2.8min
Selectivity/sensitivity
(absence of PHT)
Good peak diﬀerentiation and quantiﬁcation
of PHT. All blank samples were negative
(no presence of PHT)
All blank samples were negative
(no presence of PHT)
Recovery 94.1% for QC2 (100 ng/mL) 89.5% for QC1 (10 ng/mL)94.3% for QC5 (1000 ng/mL) 97.1% for QC3 (1600 ng/mL)
LOD (calculated as S/N ratio of 4 :1) 15 ng/mL <1 ng/mL
LOQ (calculated as 5 times the
response/blank) 50 ng/mL 10 ng/mL
Accuracy
+e calibrator values showed min–max
percent deviations of 1–20% for
Cal 1 (50 ng/mL) to Cal 6 (1200 ng/mL)
+e calibrator values showed min–max
percent deviations of 1–8% for
Cal 1 (10 ng/mL) to Cal 8 (2000 ng/mL)
Regression coeﬃcient, r2
r2blood � 0.998 (n� 2)
r2dialysate � 0.999 (n� 8)
r2saliva � 0.999 (n� 2)
r2blood � 0. 996 (n� 3)
r2dialysate � 0.997 (n� 6)
r2saliva � 0.995 (n� 3)
Calibration range 50–1200 ng/mL 10–2000 ng/mL
Run time per analysis 30min 7min
Injection volume of the sample 2.0 µL 10 µL
Sample preparation time 5 h for 25 samples 6 h for 182 samples
Stability of the processed samples
Dried extracts were stable for ≥4 weeks
(min/max deviation 4%). No eﬀect by reinjection
and storage (33 h) on the autosampler
Reinjection after 7 days showed
no diﬀerence in accuracy
Sample volume needed 50 µL 25 µL
Journal of Analytical Methods in Chemistry 5
3.3. Comparison of the LC-MS/MS Method with a Formerly
Established LC-MS/MS Method. Recently, a LC-MS/MS
method has been developed which measures PHT in blood
plasma or serum [10]. For the measurement of PHT in blood,
the newly validated LC-MS/MS method can hence also be
compared with this recently published study. e two
methods show some similarities such as an identical IS
(100 µg/mL PHT-d10), similar sample volumes needed (25 µL
versus 20 µL [10]), and a comparable retention time (2.8min
versus approximately 2.1min [10]). Both methods showed
linear regression coe©cients (r2) higher than 0.99 in the blood
matrix. e accuracy was similar as both studies showed
deviations of <10%. With regard to the calibration range and
the calibration solution, the two LC-MS/MS methods dier.
While the LC-MS/MSmethod developed in this study showed
a calibration range from 10ng/mL to 2000 ng/mL, the cali-
bration curve of the published LC-MS/MS method [10]
ranged from 100 ng/mL to 4000ng/mL. e calibration so-
lution in the current studywas the respective biological matrix
(e.g., blood). In the published study [10], phosphate-buered
saline was used as the calibration solution.
4. Discussion
In this study, a LC-MS/MS method to measure PHT in
dierent biological samples was successfully validated and
compared with a similarly validated GC-MS method [8].
Overall, the LC-MS/MS method showed to be a more
specic analytical method with a higher general perfor-
mance (Table 2).e LC-MS/MSmethod needed less sample
volume, less chemicals, and less analytical time and therefore
resulted in less costs for the sample preparation.
Concerning the LOD, there was a huge dierence be-
tween the two methods.e LOD of the LC-MS/MS method
was 15 times better than the one of the GC-MS methods: the
LOD of the LC-MS/MS method was <1 ng/mL compared to
15 ng/mL for the GC-MS method (increments by a factor of
ten). Similarly, the dierence in LOQ was 5 times lower in
LC-MS/MS (10 ng/ml) compared to GC-MS (50 ng/mL).e
LOQ for the LC-MS/MS could be set even lower than
10 ng/ml PHT (Cal 1). e FDA guidelines which claim
a minimal reproducibility at the LOQ level of 20% were well
below (deviation to target PHT amount: <8% in aCSF (n 6),<4% in blood (n 3), <9% in saliva (n 3); accuracy: aCSF
103%, blood 101%, and saliva 106%). e LOQ of the GC-
MS method and hence the lowest concentration level (Cal 1
at 50 ng/ml) of the calibration curve showed a deviation
value of 19%. e LC-MS/MS method, in contrast, showed
a value of only 3% deviation at the lowest Cal (10 ng/mL).
is dierence is of high importance, as samples with even
lower concentrations could be reliably analyzed.
e calibration range (from 10 ng/mL to 2000 ng/mL) of
the LC-MS/MS method was twice as large as of the GC-MS
method (50 ng/mL to 1200 ng/mL). is indicates that the
LC-MS/MS method is more powerful and eective over
a larger range of concentration, since the linearity is given
over a larger area (10 ng/mL–2000 ng/mL) compared to the
GC-MS method (50 ng/mL–1200 ng/mL).
As IS, two dierent substances were used. MPPH as
a structurally related compound was used for the GC-MS
method. As IS for LC-MS/MS, deuterated PHT (PHT-D10)
was used, which is the same molecule as PHT and diers only
by the molecular mass (+1). All the physicochemical pro-
cesses upon cleanup and analysis are identical or highly
Sample 
collected 
during 30 min
Aliquot of 
50 µl +  
450 µl 
matrix 
+ IS
Reconstitution 
and methylation
(derivatization)
SPE
(1) Acetonitrile (1 ml)
(2) Citric buﬀer pH 5 (1 ml)
(3) Sample
(4) Citric buﬀer pH 5 (1 ml)
(5) Acetic acid (1 ml)
(6) Elute with acetone (2x with 1 ml)
aCSF
Semipermeable 
membrane
Inlet 
(perfusate)
Flow rate 
(2 µl/min)
Injection 
of 2 µl
Blood 
sample
Saliva 
sample
Outlet 
(dialysate)
Figure 4: Sample preparation for the GC-MS analyses [8].
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similar for PHT and PHT-D10. MMPH, however, could be
chemically aﬀected in a diﬀerent way than PHT, which could
lead to a systematic bias in a given situation [15].
Regarding the sample preparation procedure, the LC-
MS/MS (Figure 1) showed an important advantage com-
pared to the GC-MS method as it only needs 3 steps of
sample preparation compared to 11 steps necessary for the
GC-MS method including a solid-phase extraction (SPE)
and derivatization with a more critical chemical trime-
thylsulfonium (TMSH) (Figure 4). +is resulted in signiﬁ-
cant shortening of the overall analysis: Preparation of the
samples before injection for GC-MS is about ten times more
time consuming than for the LC-MS/MS. For the GC-MS
method, researchers needed 5 hours to prepare 25 samples (5
samples/h), whereas for the LC-MS/MSmethod 182 samples
were prepared in 6 hours (30.3 samples/h), which corre-
sponds to 6 times the amount of prepared samples per hour
compared to the GC-MS method.
From the exposure side, the volumes are much larger
and the exposure to the chemicals aremore prolongedwith the
GC-MS method compared to the sample cleanup for the LC-
MS/MS method. Especially, the derivatization agent TMSH is
critical to handle because of toxicity. +e risk of serious and
even irreversible eﬀects through inhalation, skin contact, or
eye exposure is well known. TMSH is also considered to be
teratogenic. +erefore, the potential health risk for the labo-
ratory staﬀ handling the samples can be reduced by the LC-
MS/MS method and the elimination of a safety critical agent.
+e amount of biological samples needed for the GC-MS
method (50 µL) was twice as much as for the LC-MS/MS
(25 µL). +e sample volume is a critical point for PK/PD
studies, where, for example, by continuing dialysis from
brain in neurosurgical patients only small volumes of
samples per time point/period are available. For 50 µL di-
alysate about 25 minutes collecting time is necessary at the
usual ﬂow rate of ∼2 µL per minute [12, 16]. +erefore, not
a requested speciﬁc time point, but a rather large time
segment is represented which can inﬂuence the requested
results. +e reduced sample volume needed (25 µL) for the
LC-MS/MS analyses reduces the dialyses time needed per
sample to about 15 minutes. +e smaller the dialysis time,
the more precise correlations of the respective tissue con-
centration with plasma/blood samples can be made.
Furthermore, LC-MS/MS also has the shorter run time.
+e time needed for 100 GC-MS analyses would be ap-
proximately 50 hours. +e LC-MS/MS method, in contrast,
needs only 11 hours and 40 minutes for 100 analyses. +is is
a time saving of more than 38 hours. While this may not be
highly relevant for forensic purposes, for bedside and
routine analyses (real-time) and PK/PD studies with larger
numbers of samples, this factor is relevant. Also, when the
time between taking a sample and the result needed is short,
as it is in TDM to adjust subsequent dosing for PHT
treatment, this time saving is crucial.
+e costs for one way materials per sample was about
50% lower for the LC-MS/MS compared to the GC-MS
method. Especially because no SPE device was needed. Also,
the reduced work load for the laboratory technician must be
considered as an imported cost factor.
Finally, the appropriateness of the method also depends on
the biological matrix. Both methods can generally be used to
measure PHT in blood and saliva, as the sample volume is less
limiting. As mentioned before, however, for dialysates, the
most diﬃcult aspect is to get enough sample volume.+erefore,
the LC-MS/MSmethod needing only half of the sample volume
compared to the GC-MS method is more suited for micro-
dialysate measurements. With respect to the LOD/LOQ, the
LC-MS/MSmethod is also better suited for PK/PD studies, as it
allows to include patients with low PHT dosages.
In addition, the newly established LC-MS/MS method
was compared with a recently published LC-MS/MS method
[10]. While this study measured PHT only in one body
compartment (i.e., blood plasma or serum), the current LC-
MS/MS method was developed and validated for the mea-
surement of PHT in diﬀerent body compartments (i.e., blood,
saliva, and samples from brain tissue microdialysis often used
in neurology and neurosurgery). +e calibration range of the
published LC-MS/MS method [10] (from 100ng/mL to
4000 ng/mL) is appropriate for the measurement of PHT in
blood plasma. As the PHT concentrations in brain tissue
dialysates are much smaller than in blood plasma, the LC-
MS/MSmethod of the current studywasmore appropriate for
such samples, showing a lower calibration range from
10 ng/mL to 2000 ng/mL. Finally, as the aim of this study was
to measure PHT in diﬀerent biological matrices, a general
substitute solution for blood plasma such as phosphate-
buﬀered saline [10] could not be used. Instead, the ﬂuid of
the respective body compartment was used as calibration
solution (e.g., artiﬁcial cerebrospinal ﬂuid (aCSF) for the
measurement of PHT in the brain tissue dialysates). +is also
eliminates a potential analytical bias due to matrix eﬀects.
5. Conclusion
In this study, a LC-MS/MS method to measure PHT in
diﬀerent biological samples (i.e., human brain dialysate,
blood, and saliva) was developed and validated under cir-
cumstances that ensured a high comparability with an
established GC-MSmethod [8]. Overall, the study concludes
that LC-MS/MS is not only better performing in human
PHT concentration measuring or comparable drug PK/PD
studies but is the only one to be used for bedside analysis.
+e time-consuming sample preparation and the long run
time of the GC-MS method delay the result, which is critical
in TDM. +e higher sensitivity, the smaller needed sample
volume, the better LOD/LOQ, the less time-consuming
cleaningup and sample preparation procedure, and the
shorter run time make the LC-MS/MS method the preferred
analytical procedure.
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